Suchergebnisse
Suchergebnisse:
Adrecizumab ist ein humanisierter monoklonaler Antikörper, der das vasoaktive Peptidhormon Adrenomedullin hochspezifisch bindet, ohne seine biologische Aktivität zu blockieren. Adrenomedullin ist ein protektiver Faktor der Blutgefäßintegrität, der dem Austritt von Flüssigkeit aus dem Gefäßen entgegenwirkt.
The Company’s lead product candidate is Enibarcimab (INN, former name: Adrecizumab), a clinical-stage, first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat life-threatening conditions associated with increased vascular leakage, congestion and ...
Adrecizumab (HAM8101), ein monoklonaler Antikörper, wird derzeit zur Behandlung der Störung der Endothelfunktion bei septischem Schock, der als lebensbedrohliche Komplikation bei Infektionskrankheiten entstehen kann, entwickelt.
2. Dez. 2021 · Adrecizumab is a first-in-class antibody that targets adrenomedullin, a vasoprotective peptide, to restore vascular integrity in patients with early septic shock. Adrenomed has received positive feedback from EMA for its planned pivotal trial, which will investigate Adrecizumab on top of standard of care in ICU patients.
- The Complexity of Sepsis
- ADM: Key Regulator of The Endothelial Barrier
- Adrecizumab: Precision Medicine For Acute Care
- GeneratedCaptionsTabForHeroSec
Sepsis is a complex disorder or syndrome that presents as a cluster of symptoms and biological changes driven by diverse underlying processes, rather than a single disease with a clear-cut aetiology. Sepsis begins with an infection—bacterial, viral or fungal—that initiates a systemic inflammatory response. This, in turn, drives loss of vascular int...
Adrenomed’s goal is to fill the gap in patient treatment further downstream of inflammation with Adrecizumab, the first sepsis therapy candidate to target an important causal pathophysiology of the condition—loss of vascular integrity and endothelial barrier function—rather than merely offering symptomatic or supportive relief. ADM is a free-circul...
Adrecizumab binds to ADM inside of the blood vessel, but does not block its action. Instead, Adrecizumab sequesters ADM in the bloodstream, as the ADM-antibody complex is too large to cross the endothelial barrier. In addition, the complex with Adrecizumab increases the half-life of ADM, which ordinarily is about 20 minutes, in a dose-dependent man...
Adrecizumab is a non-blocking monoclonal antibody that binds to and stabilizes adrenomedullin, a peptide hormone that regulates endothelial barrier function. Adrecizumab is a precision medicine approach to sepsis, as it targets the loss of vascular integrity and organ failure caused by dysregulated inflammation.
Areas covered: Adrecizumab (ADZ) (HAM 8101) is a humanized targeted therapy directed against the N-terminus of adrenomedullin (ADM). ADZ inhibits excessive circulating sepsis-induced ADM and stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects.
24. Aug. 2020 · Der Anti-Adrenomedullin-Antikörper Adrecizumab hat in einer kleinen Fallserie bei schwer kranken Covid-19-Patienten gute Ergebnisse gezeigt. Zugelassen ist der Wirkstoffkandidat bislang aber nicht und größere Studien sind wünschenswert, um endgültige Aussagen treffen zu können.
